|1.||Tamaki, Kunihiko: 9 articles (11/2009 - 10/2002)|
|2.||Nakamura, Koichiro: 6 articles (11/2004 - 10/2002)|
|3.||Kakinuma, Takashi: 6 articles (11/2004 - 10/2002)|
|4.||Matsushima, K: 6 articles (02/2003 - 08/2000)|
|5.||Saeki, Hidehisa: 5 articles (08/2006 - 10/2002)|
|6.||Wakugawa, Motoshi: 5 articles (11/2004 - 10/2002)|
|7.||Pawankar, Ruby: 4 articles (07/2011 - 06/2008)|
|8.||Nonaka, Manabu: 4 articles (07/2011 - 06/2008)|
|9.||Yagi, Toshiaki: 4 articles (07/2011 - 06/2008)|
|10.||Maeda, Sadatoshi: 4 articles (02/2011 - 09/2002)|
|1.||Asthma (Bronchial Asthma)
04/01/2003 - "Recent studies suggested the T-helper cells type-2 lymphocytes-specific thymus and activation-regulated chemokine (TARC) and monocyte-derived chemokine (MDC) are useful inflammatory markers for chronic asthma. "
01/01/2005 - "Effects of corticosteroid on the expression of thymus and activation-regulated chemokine in a murine model of allergic asthma."
09/01/2002 - "Plasma concentration of thymus and activation-regulated chemokine is elevated in childhood asthma."
01/01/2003 - "Th2-specific chemokine thymus and activation-regulated chemokine (TARC)/CC chemokine ligand (CCL)17 is highly implicated in the pathogenesis of Th-2-dominated allergic diseases such as bronchial asthma (BA) and atopic dermatitis (AD). "
05/01/2005 - "Experimental data from a model of chronic fungal asthma demonstrate that thymus associated and regulated chemokine (TARC/CCL17) and macrophage derived chemokine (MDC/CCL22), working via CCR4, directly impair the innate anti-fungal immune response, thereby promoting the maintenance of acquired Th2-mediated asthmatic disease. "
|2.||Hodgkin Disease (Hodgkin's Disease)
03/01/2012 - "To define its value as a marker to monitor treatment response, we correlated serial plasma thymus and activation-regulated chemokine levels with clinical response in newly diagnosed and relapsed classical Hodgkin's lymphoma patients. "
03/01/2012 - "Plasma thymus and activation-regulated chemokine is a potential biomarker for classical Hodgkin's lymphoma. "
03/01/2012 - "Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma."
01/01/2009 - "An important prognostic marker in Hodgkin's lymphoma appears to be the chemokine (C-C motif) ligand 17 (CCL17), also known as thymus and activation-related chemokine (TARC). "
01/01/2009 - "The biological environment of Hodgkin's lymphoma and the role of the chemokine CCL17/TARC."
10/01/2014 - "Thymus and activation-regulated chemokine (TARC) can stimulate cancer cell proliferation and migration. "
03/01/2012 - "Baseline plasma thymus and activation-regulated chemokine levels correlated with stage of disease and bulky disease, and more closely with metabolic tumor volume. "
09/01/2006 - "In chemotaxis assays, CCR4 tumor cells in MF and CXCR3 tumor cells in CD8TCL migrated to thymus and activation-regulated chemokine and inducible protein-10, respectively. "
01/01/2015 - "Chemokine CCL17 induced by hypoxia promotes the proliferation of cervical cancer cell."
01/01/2015 - "Circulating thymus and activation-regulated chemokine/CC chemokine ligand 17 is a strong candidate diagnostic marker for interstitial lung disease in patients with malignant tumors: a result from a pilot study."
|4.||Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous)
08/01/2007 - "Moreover, treatment with the thymus and activation-regulated chemokine (CCL17)-expressing chemotoxin efficiently eradicated CCR4-expressing cutaneous T cell lymphoma/leukemia established in NOD-SCID mice. "
01/01/2013 - "Serum soluble CD26 levels: diagnostic efficiency for atopic dermatitis, cutaneous T-cell lymphoma and psoriasis in combination with serum thymus and activation-regulated chemokine levels."
|3.||Immunoglobulin E (IgE)
|4.||Interleukin-4 (Interleukin 4)
|5.||Interleukin-5 (Interleukin 5)
|6.||Messenger RNA (mRNA)
|10.||Transforming Growth Factor beta (TGF-beta)
|2.||Stem Cell Transplantation